Abstract 4199: HPV prevalence of cervical cancer in the United States 2014-2015

Abstract

Abstract INTRODUCTION: To determine the prevalence of human papillomavirus (HPV) types in invasive and in situ cervical cancers identified in three US population-based cancer registries (PBCRs) approximately 10 years after HPV vaccine implementation. METHODS: Archived tissue from invasive cervical cancer (ICC) and cervical carcinoma in situ (CCIS) diagnosed between 2014 and 2015 were identified from three PBCRs in Iowa, Kentucky, and Louisiana. HPV genotyping was performed using Linear Array (Roche Diagnostics); follow-up testing of HPV-negative samples was done with INNO-LiPA HPV Genotyping Assay (Innogenetics). Type-specific weighted HPV prevalences among ICC and CCIS were estimated using the hierarchical proportion to HPV 16 and 18 oncogenic genotypes included in all vaccine formulations (16/18) and protection from five additional types in the 9-valent vaccine (31/33/45/52/58). Comparisons were made with a similar study of seven PBCRs with cervical tumor tissue obtained from diagnoses between 1994 and 2005. RESULTS: A total of 363 ICC and 350 CCIS were successfully genotyped. Prevalence of HPV16/18 and HPV31/33/45/52/58 types were: ICC: [16/18: 69%, 31/33/45/52/58: 10%] and CCIS: [16/18: 68%, 31/33/45/52/58: 22%]. HPV prevalence in the 1994-2005 study was: ICC (n=777): [16/18: 67%, 31/33/45/52/58: 14%] and CCIS (n=481): [16/18: 61%, 31/33/45/52/58: 22%]. No overall changes were observed in the prevalence of HPV16/18 and HPV31/33/45/52/58 between the two studies. CONCLUSIONS: Given the long latency period of HPV-related cancers, continuing to monitor HPV prevalence in invasive and in situ cervical cancers will be important for evaluating the impact of the HPV vaccine on genotype prevalence. Citation Format: Jacqueline M. Mix, Elizabeth Unger, Troy Querec, Trevor Thompson, April Greek, Thomas Tucker, Charles Lynch, Edward Peters, Mona Saraiya. HPV prevalence of cervical cancer in the United States 2014-2015 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4199.